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ARTICLE OPEN
Health beneﬁts of late-onset metformin treatment every other
week in mice
Irene Alfaras1, Sarah J. Mitchell1, Hector Mora1, Darisbeth Rosario Lugo1, Alessandra Warren2, Ignacio Navas-Enamorado1,
Vickie Hoffmann3, Christopher Hine4, James R. Mitchell4, David G. Le Couteur2,5, Victoria C. Cogger2,5, Michel Bernier1 and
Rafael de Cabo 1
Chronic 1% metformin treatment is nephrotoxic in mice, but this dose may nonetheless confer health beneﬁts if given
intermittently rather than continuously. Here, we examined the effects of 1% metformin given every-other week (EOW) or two
consecutive weeks per month (2WM) on survival of 2-year-old male mice fed standard chow. EOW and 2WM mice had comparable
life span compared with control mice. A signiﬁcant reduction in body weight within the ﬁrst few weeks of metformin treatment was
observed without impact on food consumption and energy expenditure. Moreover, there were differences in the action of
metformin on metabolic markers between the EOW and 2WM groups, with EOW metformin conferring greater beneﬁts. Age-
associated kidney lesions became more pronounced with metformin, although without pathological consequences. In the liver,
metformin treatment led to an overall reduction in steatosis and was accompanied by distinct transcriptomic and metabolomic
signatures in response to EOW versus 2WM regimens. Thus, the absence of adverse outcomes associated with chronic, intermittent
use of 1% metformin in old mice has clinical translatability into the biology of aging in humans.
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INTRODUCTION
Metformin is a biguanide used extensively since the 1960s in the
treatment of type 2 diabetes. Metformin has an established safety
record and its current approved indication is to improve glycemic
control in adults and children with type 2 diabetes mellitus along
with diet and exercise.1 Recent studies in preclinical models also
support a novel role of metformin in improving healthspan and
lifespan.2–6
The primary target of metformin appears to be the mitochon-
drion through inhibition of complex I of the respiratory chain7,8
and mitochondrial glycerol-3-phosphate dehydrogenase.9 The
ensuing perturbations in cellular energy status and redox home-
ostasis result in activation of the energy sensor AMP-activated
protein kinase (AMPK). AMPK-independent actions of metformin
have been also described,10–14 which include the reduction in
mTOR/p70S6K activity resulting from Rag GTPase inhibition.10 The
anti-gluconeogenic action of metformin is preserved in liver-
speciﬁc AMPK knockout mice.13 Moreover, this biguanide confers
protection against certain cancers by inhibiting mTOR/p70S6K
activity in an AMPK-independent manner,15 and reduces the
tumorigenicity of induced pluripotent stem cells while maintain-
ing their pluripotency.16 Impaired cellular senescence and
accumulation of DNA damage contribute to aging17 and
metformin has been shown to trigger an immune-mediated
clearance of senescent cells by activating an ATM-dependent DNA
damage response.18 The ability of metformin to lower the
incidence of diabetes-associated cardiovascular events and risk
of cancer without interfering with stem cell pluripotency may have
important implications for a number of age-related diseases that
affect lifespan (for recent review19).
Metformin is a calorie restriction (CR) mimetic, with several of its
metabolic actions, particularly those related to glucose metabo-
lism, resembling to some extent those of CR.2,3,20,21 Our previous
study showed that diet supplementation with a low dose of
metformin (0.1% w/w) improves healthspan and extends lifespan
when treatment was started in mice at middle age.2 However,
long-term exposure to a high dose of metformin (e.g., 1%) is
nephrotoxic and leads to early mortality in mice even though
global gene expression proﬁle appears to be closer to CR when
given only for a short period of time.2 Nevertheless, there has
been a recent ﬂurry of interest in the use of metformin in clinical
translational research on aging. In that regard, a new clinical trial
has been set up to investigate the health beneﬁts of chronic
metformin treatment and determine whether it can induce dietary
restriction-like state in humans (ClinicalTrials.gov Identiﬁer:
NCT02745886). A second clinical study, which is known as the
“Targeting Aging with Metformin” study, aims at assessing the
potential of a pharmacological intervention in delaying age-
associated diseases beyond metformin’s isolated impact on
diabetes.22 A similar paradigm is currently being tested in the
pilot study known as “Metformin in Longevity Study” (Clinical-
Trials.gov Identiﬁer: NCT02432287). In the latter trial, investigators
will search for gene expression changes in adults 60 years and
older to provide initial clues on how and whether an older
molecular and genomic signature can be reverted to a younger
one. These studies will take years before providing meaningful
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information on the healthspan and lifespan potential of metfor-
min in humans.
In order to provide timely insights into the potential pro-
longevity beneﬁts of this drug, we set out to examine the effect of
intermittent treatment with 1% metformin given either every-
other-week (EOW) or two consecutive weeks per month (2WM) in
2-year-old male mice. We chose EOW and 2WM in order to
potentially reduce the impact and incidence of nephrotoxicity
observed in our previous study, while conferring CR-like health
beneﬁts.2 The results indicate that intermittent metformin
treatment did not lead to early mortality and that EOW metformin
improves some metabolic markers of health without promoting
lifespan extension when treatment is initiated in late-life in mice.
The mechanisms potentially underlying these effects are
discussed.
RESULTS
Animal characteristics in response to intermittent metformin
treatment
Daily exposure to low dose of metformin (0.1% w/w in diet)
confers healthspan beneﬁts and extends lifespan when given to
middle-age male mice while a higher dose (1% w/w) was found to
be toxic.2 Here, we asked whether intermittent feeding with 1%
metformin in the diet could confer protection in the absence of
toxicity in a cohort of 2-year-old male mice.
Male C57BL/6 mice were fed a standard AIN-93G diet (SD)
supplemented with 1% metformin EOW or for 2 consecutive
weeks each month (2WM) for the remainder of their lives (n = ~65
mice per experimental group × 3 groups). The collection of blood
samples and measures of physiological/biochemical parameters
was carried out as depicted in Fig. 1a. EOW and 2WM metformin
treatment did not alter mean or maximum lifespan of mice
(Fig. 1b, Supplementary Table S1), and gross necropsy examina-
tion on all mice that died revealed no histopathological
differences between experimental groups (Supplementary
Table S2) consistent with the lifespan data. The absence of major
renal pathologies at the time of death in mice subjected to
intermittent 1% metformin treatment was in sharp contrast to the
apparent renal failure observed in mice on chronic, daily 1%
metformin.2 EOW and 2WM mice consumed about 1 g metformin
kg−1 body weight per day, which translates to about 80 mg
metformin kg−1 body weight in humans,23 a dosage that is more
than twice the maximum dose of metformin that patients receive
(3 × 850 mg per day). Weight trajectory of the three groups is
shown in Fig. 1c, with a greater decrease of weight in the ﬁrst few
weeks of treatment in EOW and 2WM mice compared to control
animals. While the SD group lost 2.04 g by 10 weeks, metformin
treatment caused a signiﬁcant weight reduction by more than
6.98 and 6.51 g in EOW and 2WM mice, respectively (Fig. 1c inset).
All three groups demonstrated comparable body weight trajec-
tories by 20 weeks of treatment. The body temperature and food
consumption levels were also similar over the ~55-week treatment
(Fig. 1d, e). Although the average daily food consumption per
mouse was unaffected (Fig. 1f), there was signiﬁcant reduction in
food intake when mice were on metformin compared to mice
getting off the drug (Fig. 1g). Intermittent metformin treatment
maintained the positive association between % body fat
(measured by nuclear magnetic resonance (NMR) after 16 weeks
of treatment) and lifespan (Fig. 1h, upper panel), which coincided
with an inverse relationship between the lean-to-fat ratio and
maximal survival (Fig. 1h, lower panel).
To assess the effect of metformin on in vivo energy metabolism,
indirect calorimetry was performed for 48 h using the CLAMS
system. The daily cycling of the respiratory exchange ratio (RER;
CO2 production vs O2 consumption) in old EOW and 2WM mice
while on metformin was similar to that of SD mice (Fig. 1i–j).
However, a signiﬁcant increase in RER values in both the light and
dark cycles was observed upon the return of EOW mice to SD
without metformin, with a similar trend in 2WM mice, indicating a
proportional substrate preference toward carbohydrate utilization
for energy demands once metformin was removed from the
diet (Fig. 1i–j). Under these conditions, locomotor activity was
undistinguishable between experimental groups (Supplementary
Fig. S1a, S1b). The experiments suggest that the intermittent
removal of metformin may have inﬂuenced RER in aged animals.
A number of behavioral and locomotor tests was then
performed when old mice were on metformin and after they
were returned to SD without metformin. Overall, the removal of
metformin was associated with signiﬁcant increase in the latency
to fall from a wire hang test in both groups of mice (Fig. 1k), but
not after using the elevated wire cage top test or an accelerating
rotarod (Supplementary Fig. S1c), indicating a rather mild
improvement, if any, in motor coordination and learning. The
grip strength of mice was also unresponsive to metformin
treatment with or without correction for body weight (Supple-
mentary Fig. S1c).
We undertook a study where serum samples were collected
from four consecutive weeks (week 13–16) to determine circulat-
ing glucose and lactate levels after a 6-h fast. While being
unaffected in EOW mice, the fasting blood glucose levels were
signiﬁcantly lower in 2WM mice at week-14, representing the
second consecutive week on metformin (Fig. 1l). Increase in
plasma lactate levels is common in response to metformin due to
inhibition of hepatic mitochondrial respiration.24 Here, fasting
plasma lactate concentrations signiﬁcantly increased when mice
were exposed to metformin before returning to basal levels
during the off-periods (Fig. 1m). An additional blood chemistry
analysis was performed in non-fasting animals at 17 weeks of
treatment when both EOW and 2WM mice were on metformin.
There was signiﬁcant improvement in insulin levels and homeo-
static model assessment of insulin resistance (HOMA-IR) that did
not translate in lower blood glucose when compared to SD
controls (Fig. 1o-p versus Fig. 1n). Glycated hemoglobin A1c
(HbA1c, an indicator of the 3-mo average plasma glucose
concentration) and serum adiponectin levels were comparable
in all groups (Supplementary Fig. S1d). EOW mice exhibited
signiﬁcant increase in circulating lactate (Fig. 1q) that coincided
with a marked reduction in leptin levels (Fig. 1r) despite similar
lean-to-fat ratio as SD mice (Supplementary Fig. S1e). Comparable
trend was observed in metformin-treated 2WM mice. As
anticipated, a positive and signiﬁcant correlation between
epidydimal fat content and serum leptin levels was observed
(Fig. 1s). Although no further tests to evaluate glucose or insulin
tolerance were conducted, we observed that the triglyceride levels
in EOW livers trended lower from 54.97 ± 15.68 (SD) to 24.46 ±
4.36mg g−1 (Supplementary Fig. S1f), consistent with a possible
improvement in insulin sensitivity.25 Hydrogen sulﬁde production
mediates multiple beneﬁts normally associated with stress
resistance and longevity.26 Here, there was a near signiﬁcant
increase in hepatic production of hydrogen sulﬁde in EOW mice,
compared to SD livers (P = 0.051; Supplementary Fig. S1g).
Metformin was detected in the serum and liver extracts of EOW
and 2WM mice after 17 weeks of treatment (Fig. 1t and
Supplementary Fig. S1h). These results indicate a slight improve-
ment in the metabolic health of the aged mice exposed to
intermittent metformin.
Effect of intermittent metformin treatment on liver and kidney
histology
Aging is associated with lipid accumulation and local inﬂamma-
tion.27 Histochemical analyses were carried out on frozen-ﬁxed
liver tissues to determine the effects of intermittent metformin
treatment on hepatic steatosis, ballooning, inﬂammation, and
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glycogen deposition (Fig. 2a–f). Compared to control mice, H&E
staining of EOW and 2WM livers (Fig. 2a) revealed a signature
consistent with a reduction in steatosis (Fig. 2b), even though
biochemical quantiﬁcation of hepatic triglycerides showed only a
trend toward lower hepatic lipid accumulation (Supplementary
Fig. S1e). EOW livers displayed signiﬁcant reduction in ballooning
degeneration of hepatocytes in the absence of inﬂammation
(Fig. 2c, d) or change in glycogen deposition (Fig. 2e, f). However,
2WM treatment resulted in higher inﬂammation and periodic
acid–schiff staining (PAS) depots compared to SD controls, thus
Intermittent treatment with metformin in old mice
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highlighting differences in the effect of metformin treatment
between the EOW and 2WM livers.
Liver sinusoidal endothelial cells contain transcellular pores
known as fenestrations that enable transfer of metabolites
between blood and the surrounding hepatocytes.28 Scanning
electron microscopy (SEM) of ﬁxed liver sections was performed to
assess the integrity of the hepatic sinusoidal endothelium in mice
subjected to intermittent metformin treatment (Fig. 2g). EOW
mice exhibited greater porosity of the liver sieve than the SD and
2WM groups (Fig. 2h), and was consistent with improved insulin
sensitivity.
Kidney sections from SD, EOW and 2WM mice after 17 weeks of
treatment were examined and scored for possible toxic lesions.
Both H&E and PAS-stained slides were evaluated by a certiﬁed
veterinary pathologist. All kidneys had age-associated background
tubular lesions of varying degrees while glomerular lesions were
milder, suggesting that injury originated with the tubules (Fig. 2i).
Metformin treatment contributed to an increase in renal tubular
lesions in the EOW and 2WM cohorts compared to SD controls,
which included ﬂattening of renal tubular epithelial cells with loss
of brush borders, ceroid pigmentation of basement membranes,
and mild interstitial inﬂammation (Fig. 2i and data not shown). The
results indicate that this increased incidence in renal lesions upon
EOW and 2WM metformin has little effect, if any, on maximal
lifespan.
Hepatic gene expression proﬁles in mice under intermittent
metformin treatment
Whole-genome microarray analysis was performed on liver
samples of 2-year-old mice after 17 weeks on SD supplemented
or not with metformin. Principal component analysis (PCA)
showed a clear effect of metformin treatment on liver transcrip-
tome (Fig. 3a). To understand the determinants contributing to
the metformin response, two-way Venn diagrams were plotted
with the EOW–SD and 2WM–SD pairwise comparisons (Fig. 3b).
The number of transcripts that were upregulated (red color) and
downregulated (blue color) are depicted, with more than 196
transcripts that were shared. Heat map of the top 100 shared
genes indicated great similarity in both the magnitude and
direction of gene expression (Supplementary Fig. S2a), as only ﬁve
transcripts were regulated in opposite direction, including Idh1
and Sc5d. A list of the top 50 signiﬁcantly altered transcripts
shared in EOW and 2WM livers can be found in Supplementary
Table S3. In order to predict signiﬁcant changes in gene
expression, the Z-score transformation method accompanied by
z-ratios was used (see Supplementary Information for further
details). The effects of metformin were accompanied by marked
upregulation of Lpin1, Pck1, and several genes implicated in
cholesterol biosynthesis, with the downregulation of glucokinase
(Gck) and Saa4 whose transcript encodes the inﬂammation-
inducible serum amyloid A4 protein (Fig. 3c). Lpin1 encodes for
lipin-1 protein, which acts as a nuclear transcriptional coactivator
for the PGC1α/PPARα heterocomplex linked to fatty acid β-
oxidation.29
Parametric analysis of gene set enrichment enabled the
identiﬁcation of signiﬁcantly altered genes within 115 GO Terms,
23 of which were uniquely present in the EOW–SD comparison
(Fig. 3d, Supplementary Table S4a). The top downregulated GO
Term in EOW livers was GO0006633 ‘fatty acid biosynthetic
process’ with a Z-score of −5.604. Positive and negative scores
reveal the number of standard deviations the aggregated Z-score
of a given GO Term (or pathway) within a pairwise comparison
(e.g., EOW–SD) is either above or below the mean of all pathways
(See Supplementary Information for additional details). Among
the top GO Terms that were impacted in the 2WM–SD com-
parison were GO0008610 “lipid biosynthetic process” and
GO0006350 “transcription” with Z-scores of +13.913 and −4.459,
respectively (Supplementary Table S4b). Forty-ﬁve GO Terms were
shared between EOW and 2WM livers, which included the
upregulation of pathways implicated in ribosome/translation,
biosynthetic and metabolic processes, and signal transduction as
well as the downregulation of GO Terms associated with histone
acetylation and nucleosome assembly (Supplementary Table S4c).
Among the shared GO Terms, only three exhibited an opposite
direction in expression, which included GO0005743 ‘Mitochondrial
Inner Membrane’ and GO0005739 ‘Mitochondrion’ (Fig. 3e,
arrows). The gene expression pattern within the shared GO terms
‘cholesterol biosynthetic process’ and ‘mitochondrial inner mem-
brane’ is depicted (Supplementary Figs. 2b, 3f).
A deeper look into the liver microarray data revealed a number
of genes implicated in steatosis and insulin sensitivity that were
differentially regulated by intermittent metformin treatment. For
instance, expression of Scd1 and Hsd3b5, which strongly correlates
with the degree of hepatic steatosis30 was found to be
signiﬁcantly lower in EOW compared to 2WM and SD control
livers (Fig. 3g). Major urinary protein (MUP) 1 regulates energy
expenditure by restricting glucose production and lipogenesis
though direct inhibition of hepatic gene expression in diet-
induced obese mice.31 Here, large reduction in Mup5, Mup4, Mup1,
and Mup2 levels was observed in EOW than in 2WM and SD livers
(Fig. 3g). The decrease in hepatic Mup expression observed with
Fig. 1 Characteristics of mice on intermittent metformin treatment. a Protocol design. Male mice (108 week-old) were fed a standard diet (SD)
without (n= 68) or with 1% metformin in the diet every-other week (EOW, n= 64) or for two consecutive weeks each month (2WM, n= 67) for
24 weeks. At the indicated time points (weeks), body composition (NMR), metabolic assessment (RER), and physical performance tests (PPT)
were performed on non-fasted animals, whereas blood glucose and lactate levels were measured in 6-h fasted mice. Sac, sacriﬁce of a subset
of animals for tissue collection and analysis (SD, n= 10; EOW, n= 6; 2WM, n= 6). b Kaplan–Meier survival curve for the three experimental
groups of mice (SD, EOW, 2WM). No extension of maximal lifespan was observed. c Body weight proﬁle over the lifespan. Data include all live
animals at each time point. Inset, Body weight at the initiation (0) and after 10 weeks of treatment (10) (SD, n= 68(0) and 64(10); EOW, n= 64(0)
and 58(10); 2WM, n= 67(0) and 57(10)). #p< 0.05 compared to t= 0; *p< 0.05 compared to SD at t = 10 weeks. d Body temperature. e Food
consumption. f Average daily food consumption per mouse. g The data shown in panel f was segregated by whether mice were on metformin
treatment or returned to SD without metformin. h Correlations between % body fat (upper panel) or lean-to-fat ratio (lower panel) and time of
death (n= 12 in each group) (upper, F= 22.27; dFn, dFd (1, 35); P< 0.0001); lower, (F= 11.1; dFn, dFd (1, 35); P< 0.002). i–jMice were subjected
to metabolic assessment after 17 weeks of treatment (SD, n= 11; EOW on metformin, n= 6; EOW off metformin, n= 6; 2WM on metformin, n=
9; 2WM off metformin, n= 3): i Respiratory exchange ratio (RER) values over the course of 48 h; j RER values shown in panel i were segregated
based on the light and dark periods of the L12:D12 cycle; k Latency to fall from wire hang was measured after 16 weeks of treatment (SD, n=
47; EOW on metformin, n= 12; EOW off metformin, n= 7; 2WM on metformin, n= 0; 2WM off metformin, n= 22) before (upper panel) and
after (lower panel) correction for body weight. l, m At 13–16 weeks of treatment, mice were fasted for 6 h (SD, n= 8–10; EOW, n= 9–10; 2WM,
n= 9–10) and circulating levels of l glucose and m lactate were measured. n–r The following analyses were carried out at 17 weeks of
treatment in fed mice (SD, n= 10; EOW, n= 6; 2WM, n= 6): n blood glucose; o serum insulin levels; p HOMA-IR index; q blood lactate; r Serum
levels of leptin. s Correlation between circulating levels of leptin and amount of epididymal fat as percent body weight. t Serum levels of
metformin after 17 weeks of treatment (SD, n= 3; EOW, n= 6; 2WM, n= 6). Data are represented as the mean± s.e.m. *P< 0.05 compared to
SD-fed mice, #P< 0.05 compared to mice on metformin (Kruskal–Wallis with Dunn’s post hoc test)
Intermittent treatment with metformin in old mice
I Alfaras et al.
4
npj Aging and Mechanisms of Disease (2017)  16 Published in partnership with the Japanese Society of Anti-Aging Medicine
EOW was comparable to our recently published data in male mice
maintained on 40% CR.32 The hepatic production of MUPs is
increased by a number of hormones, including testosterone,
thyroxine, and growth hormone (GH).33 As shown in Fig. 3g, EOW
livers exhibited signiﬁcant reduction in expression of Srd5a1, a
gene implicated in the conversion of testosterone into the more
potent androgen, dihydrotestosterone, and Dio1, which converts
thyroxine to the bioactive thyroid hormone, whereas both genes
were unaffected in 2WM livers. Both fasting and metformin
treatment stimulate hepatic Igfbp-2 transcription,34,35 which is
known to negatively regulate GH signaling. The expression of
Igfbp2, whose transcript participates in the reduction in the
Intermittent treatment with metformin in old mice
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bioavailability of IGFs, was upregulated in EOW, but not 2WM
livers (Fig. 3g). Thus, EOW supplementation with metformin was
associated with possible dampening in hormonal regulation of
Mup gene expression. A select group of genes were validated by
real-time quantitative PCR (Fig. 3h). Lastly, immunoblot analysis
indicated that the steady-state levels of active AMPK phosphory-
lated at Thr-172, a known endpoint of metformin action in liver,
were comparable in the three experimental groups (Supplemen-
tary Fig. 2c, d). Similarly, phosphorylation of ACC at Ser-79, a target
of AMPK activity, was unresponsive to metformin treatment, even
though the drug reached the liver in sizeable concentrations.
To assess whether intermittent metformin treatment exhibits
CR-like transcriptomic proﬁles, we compared the main character-
istics of the current set of gene expression with that of our
previous study performed in the livers of ~2-year-old male C57BL/
6J mice on 40% CR (CR40).32 Details about the experimental
cohorts and the way the data was analyzed can be found
in Supplementary Methods. Pathway analysis showed a CR40-
dependent enrichment in gene sets associated with gluconeo-
genesis and mitochondrial bioenergetics with the downregulation
of several gene sets implicated in inﬂammation when compared
to ad libitum (AL)-fed littermates (Supplementary Fig. S2e). Two-
way Venn diagrams were then plotted with the CR40-AL and
either EOW–SD or 2WM–SD pairwise comparisons (Fig. 3i). In both
data sets, the control groups (AL and SD) were comparable. Heat
map suggested great similarity in the magnitude and direction of
expression of genes shared between CR40 and EOW livers, but
marked divergence between CR40 and 2WM livers (Fig. 3j).
Notably, more than 210 genes were shared among the three
pairwise comparisons, of which 52% (109/210) and 33% (70/210)
appeared to be absent in 2WM and EOW, respectively, and only
15% (31/210) were common for the three comparisons (Fig. 3k,
middle panel). More than 87% of the genes (61/70) shared
between CR40 and 2WM exhibited an opposite direction of
expression (Fig. 3k, left panel; Supplementary Table S5a), whereas
only 4% of the genes (4/109) common to both CR40 and EOW
displayed similar behavior (Fig. 3k, right panel; Supplementary
Table S5b). Among the genes common to EOW and CR40 livers
whose magnitude and direction of expression were similar
included Mup5, Srd5a1, Dio1, and Igfbp2 as well as select genes
such as Srebf1, Ppargc1a, and Socs2 (Fig. 3l). Moreover, Fmo3 was
the top upregulated gene in the EOW–SD and CR40-AL pairwise
comparisons, with zratios of +20.36 and +24.89, respectively
(Supplementary Table S5b, Fig. 3i). Fmo3 encodes the hepatic
drug-metabolizing enzyme, ﬂavin-containing monooxygenase 3, a
member of a conserved family of enzymes with health and
lifespan-promoting activities.36 A signiﬁcant increase in the
expression of Angptl4, whose transcript encodes the hepatic
Fibrinogen/Angiopoietin-Related protein (ANGPTL4), was also
found in EOW and CR livers (EOW–SD, zratio + 7.57; CR40-AL,
zratio + 5.56) (Supplementary Table S5b).
A binary representation of the 31 signiﬁcantly altered genes
shared between CR40, EOW, and 2WM indicated a subset of
transcripts with opposite direction of expression between inter-
mittent metformin treatment and CR (Fig. 3m, Supplementary
Table S5c): These included Fdps, Hmcgs1, and Mvd, which are
primarily involved in cholesterol and sterol biosynthesis.
Intermittent metformin treatment impacts liver and serum
metabolomics
More than 150 metabolites resulting from multiple cellular and
biological processes were identiﬁed in liver and serum samples by
untargeted liquid and gas chromatography coupled with mass
spectrometry. Volcano plots were used to visualize changes in
metabolite levels in response to EOW or 2WM treatment versus SD
controls (Fig. 4a). The metabolites signiﬁcantly impacted by the
intermittent metformin treatment (fold change ≥1.25; P≤ 0.05)
were merged in two-way Venn diagrams as a mean to identify
unique and overlapping ones (Fig. 4b). The magnitude and
direction of the levels of metabolites shared between EOW and
2WM were identical in both the serum and liver extracts (Fig. 4c;
Supplementary Table S6), and included 3-hydroxybutyric acid, a
ketone body, 2-hydroxy-2-methylbutyric acid, whose buildup
results from a defect in branched-chain amino acid metabolism,
and 2-hydroxyglutarate.
Important metabolites associated with energy and lipid
metabolism were found to be speciﬁcally reduced in EOW mice
(e.g., glycerol α-phosphate and lactate), while other molecules
such as aspartate, citrate and isocitrate were increased (p < 0.05)
(Supplementary Fig. S3a, Fig. 4d). Glycerol α-phosphate is oxidized
by mitochondrial glycerophosphate dehydrogenase (GPD2) for
transfer of cytosolic NADH to the mitochondrial electron transport
chain, and interestingly, the glucose-lowering effect of metformin
has been attributed to inhibition of this enzyme.9 The drop of
glycerol α-phosphate levels in EOW mice correlated with lower
hepatic triglyceride levels and decreased susceptibility to age-
associated metabolic disorder, e.g., hyperinsulinemia and insulin
resistance, and liver steatosis. Moreover, the improvement in
systemic insulin sensitivity after intermittent metformin treatment
in EOW mice was accompanied by signiﬁcant reduction in hepatic
palmitoleic acid, a monounsaturated fatty acid that is produced
almost exclusively through desaturation of palmitic acid by
stearoyl-CoA desaturase, whose gene expression level was also
reduced speciﬁcally in EOW livers (z ratio of −6.65; Fig. 3g). The
increased levels of 2-hydroxybutanoic acid in serum of EOW mice
were consistent with greater cleavage of cystathionine to cysteine,
which correlated with accumulation of cystine, the oxidized form
of cysteine, and hepatic hydrogen sulﬁde (Fig. 4d). Lastly,
metabolites proﬁling uncovered the presence of elevated serum
levels of the tryptophan metabolites 3-indoxyl sulfate and indole
3-lactate with concomitant depletion in tryptophan in EOW mice
(Fig. 4d).
Fig. 2 Intermittent metformin treatment reduces liver injury and improves the porosity of the mouse liver sieve. a H&E staining depicted
steatosis as circular white gaps caused when the dehydration process leaches the fat out of ﬁxed liver tissues. HFD, representative image of
ﬁxed liver section of a high-fat diet-fed mouse showing intense steatosis. c-d The following quantitative measurements were carried out: b
The degree of steatosis; c Extent of ballooning degeneration of hepatocytes; d Degree of inﬂammation. e Periodic acid–Schiff staining (PAS)
for the detection of polysaccharides (e.g., glycogen) in ﬁxed liver tissues. Young crtl, representative image of ﬁxed liver section of a young
mouse with strong glycogen deposition. f Semi-quantiﬁcation of PAS staining. a Scale bar, 200 μm; 5× ﬁnal magniﬁcation; e Scale bar, 200 μm;
10× ﬁnal magniﬁcation. g Representative scanning electron microscopy images of liver sections of the SD and EOW groups of mice. Scale bar,
1 μm; 15,000× ﬁnal magniﬁcation. h The degree of porosity seen as the fenestration area expressed as percent of total area was quantitatively
determined. All data are represented as the mean± s.e.m. *P< 0.05 compared to SD-fed mice (ANOVA with Tukey’s multiple comparisons test
and Kruskal–Wallis with Dunn’s post hoc test for PAS). #P< 0.05 compared to EOW-treated mice (ANOVA with Tukey’s multiple comparisons
test). i Heatmap of the average score of various types of tubular and glomerular lesions in each experimental group of mice (SD, n= 10; EOW,
n= 6; 2WM, n= 6). Bars represent the mean± s.e.m. of selected tubulointersitial lesions. See “Methods” for additional information. *P< 0.05,
**P< 0.01, ***P< 0.001. SD standard diet
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DISCUSSION
Although the use of metformin as a pro-longevity strategy has
been proposed when started early in life,3 our analysis reveals that
the intermittent use of the drug confers some health beneﬁts in
the absence of extended lifespan when the treatment was
initiated in late-life in male mice. Using a multi-system approach
(transcriptomic and metabolomics), this work illustrates the
complexity of metformin’s physiological effects and underscores
the need for a comprehensive assessment of the interaction that
exists between metabolic dysfunction and aging phenotypic
outcomes.
In addition to its involvement in lowering hepatic glucose
production, metformin has recently been implicated as a direct
regulator of metabolism, with actions including activation of a
Intermittent treatment with metformin in old mice
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neuronal-mediated gut–brain–liver pathway,37 reduction in the
rate of small intestinal glucose absorption to enhance postpran-
drial secretion of glucagon-like peptide-1,38 targeting of central
carbon metabolism,39 anti-cancer protection,40 and the regulation
of microRNA expression and cellular senescence.41 The present
study demonstrates signiﬁcant improvement in insulin sensitivity
in non-fasted old mice subjected to intermittent metformin
treatment for 17 weeks. This was evidenced by lower circulating
insulin levels and HOMA-IR index, despite maintenance of blood
glucose levels within the range seen with SD mice. This metformin
protocol also reduced fasting plasma glucose and improved
insulin sensitivity without translating into lifespan extension, even
though limiting basal insulin levels in old mice has been recently
reported to exert a positive effect on lifespan.42 We observed
lower circulating leptin levels in the metformin-treated mice than
in SD controls despite similar lean-to-fat ratio, supporting the idea
that this drug is acting as a leptin sensitizer by increasing hepatic
and hypothalamic leptin receptor expression.43,44
The rapid weight loss early in the metformin treatment could
not be explained by the decrease in food intake or increase in
foraging activity, but instead may have been the product of
heightened rates of metabolic processes. Examination of the 24-
month-old mice in the CLAMS monitoring system revealed the
inability of metformin at promoting mitochondrial fatty acid
oxidation during light cycle. Moreover, the removal of the drug
during the intermittent metformin treatment was accompanied by
a shift in carbohydrate utilization in both the light and dark cycles
of EOW mice (RER values of 0.95 and 1.0, respectively), with a
similar trend observed in the 2WM group. The greater reliance on
sugar metabolism during the off-metformin period may be
reﬂected by falling circulating lactate levels due to increased
production of pyruvate and its ultimate conversion to ATP via
aerobic metabolism through complex I of the respiratory chain.
The expression of hepatic genes involved in cholesterol
biosynthesis, gluconeogenesis, and ribosome/translation were
upregulated following chronic intermittent treatment of old mice
with metformin for 17 weeks. Even though metformin has been
shown to inhibit hepatic glucose production, a recent study using
oral administration of glucose-1-13C in mice on high-fat diet
reports on the increased conversion of labeled glucose to lactate-
3-13C in the intestinal wall due to inhibition of complex I of the
mitochondrial respiratory chain7,45 by metformin, and release of
lactate-3-13C into the portal vein with subsequent generation of
doubly labeled glucose-1,6-13C molecules in the liver via
gluconeogenesis.46 The authors propose that this “futile”
intestinal–zhepatic cycle is very energy consuming and could
explain some of the reduced weight gain seen in HFD-fed mice on
metformin. We reasoned that a similar mechanism could be
implicated in the initial weight loss observed in old mice enrolled
in the intermittent metformin program.
There are alterations in hepatic AMPK activity during normal
aging in mice.47 It follows that major impact on hepatic lipid and
glucose metabolism and energy production is expected when
comparing young and old animals. Indeed, our preliminary data
clearly showed that the daily cycling of energy expenditure over a
48-h period is markedly dampened with age, with RER values
signiﬁcantly higher during the light phase in 24-mo-old C57Bl/6
mice compared to 5-mo-old animals. These results are consistent
with an age-associated substrate preference toward carbohydrate
utilization for energy demand at the expense of fatty acid β-
oxidation.
Because behavioral and motor coordination tests as well as the
metabolic panel blood analyses were carried out at a single time
point (e.g., 17 weeks of intermittent metformin treatment) instead
of longitudinally, this study does not provide sufﬁcient informa-
tion to conclude that metformin promotes healthspan in aged
mice. Despite the limitation of the study, several positive
outcomes were observed in the liver of EOW mice, notably by
histology and SEM, including improvement in the age-related
changes in the porosity of the liver sieve.28,48 The integrity of the
liver sieve is essential for the maintenance of insulin, glucose, and
lipid metabolism and clearance of ingested and gut microbiota-
derived metabolites.49 Aging predisposes the liver to chronic low-
grade inﬂammation and oxidative damage that can contribute to
the development of ﬁbrosis and non-alcoholic fatty liver disease,
which can evolve into non-alcoholic steatohepatitis in the absence
of diet-induced obesity and type 2 diabetes.50,51 A recent study
reported that the age-dependent increase in hepatic steatosis
relates to cellular senescence.52 The ability of metformin to
decrease cellular senescence and lower the abundance of
inﬂammatory cytokines in several senescence models41 is in
agreement with our ﬁndings that showed signiﬁcant reduction in
hepatic steatosis and liver injury in EOW mice. The failure to
maintain homeostasis and adapt to environmental changes drives
the pathogenesis of age-related disease of the liver. It is possible
that some of the protection against hepatic inﬂammation in the
aged EOWmice on metformin relates to the modulation of the gut
Fig. 3 Intermittent metformin treatment alters the global hepatic gene expression proﬁle of SD-fed mice. a Principal component analysis
(PCA) from microarray RNA experiments in livers of 108-week-old mice maintained for 17 weeks on 1% metformin either EOW or 2WM
compared with SD controls (SD, n= 4; EOW, n= 4; 2WM, n= 4). b Venn diagram of upregulated (red), downregulated (blue), and reciprocally
regulated (black) gene transcripts between the EOW–SD and 2WM–SD pairwise comparisons. c Graphical representation of select genes
signiﬁcantly impacted by EOW and 2WM. As indicated in Methods, the measure in gene expression uses Z-score transformation of the
normalized data, accompanied by z-ratios for predicting signiﬁcant changes.73, 74 d Venn diagram of upregulated (red), downregulated (blue),
and reciprocally regulated (black) GO Terms between the EOW–SD and 2WM–SD pairwise comparisons. e Graphical representation of the
signiﬁcant 45 GO Terms shared by EOW (plotted in blue) and 2WM (plotted in red). Zscores depict the number of standard deviations, either
above or below the mean of all pathways, the aggregated Z-score of a given GO Term (or pathway) has within a pairwise comparison (see
Methods for additional details). The list of all the signiﬁcantly modiﬁed GO Terms can be found in Supplementary Table S4c. Arrows depict 3
GO Terms with changes (Z-score) shifted in the opposite direction between the two pairwise comparisons. f Expression of genes within the
GO Term “Mitochondrial inner membrane” is depicted as Z ratios. g Expression of genes signiﬁcantly altered only in the EOW–SD comparison.
h Validation of the microarray data by quantitative RT-PCR. Data are represented as the mean ± s.e.m. *P< 0.05 compared to SD-fed mice (t-
test two tailed). SD, standard diet. i–m Exploratory data analysis aimed at visualizing the main characteristics of the current set of gene
expression with that of our recent study on the chronic effect of 40% calorie restriction versus ad libitum feeding (CR40-AL) in male C57BL/6J
mice.32 i Venn diagram of upregulated (red), downregulated (blue), and reciprocally regulated (black) gene transcripts in the livers of CR40-AL
versus either EOW–SD (upper panel) or 2WM–SD (lower panel) pairwise comparisons. j Heat map comparing the expression of liver transcripts
common between EOW–SD and CR40-AL or 2WM–SD and CR40-AL. k Distribution of the 210 transcripts shared between EOW–SD and CR40-
AL (109), 2WM–SD and CR40-AL (70), or all three comparisons (31) (middle panel). More than 87% of transcripts shared between 2WM–SD and
CR40-AL (61/70) were in the opposite direction (left panel), whereas the large majority (96%) of transcripts shared between EOW–SD and
CR40-AL followed the same direction (right panel). l Change in expression of select genes common between EOW–SD and 40CR-AL is
depicted as z-ratios. m Binary representation of gene expression related to the 31 transcripts (k, middle panel) shared between the three
pairwise comparisons. Upregulated, red boxes; downregulated, blue boxes. The complete list of genes is provided in the Supplementary
Table S5c
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microbiota through activation of the immune system.53 Clearly,
more work is needed to validate this hypothesis.
Metformin-associated lactic acidosis is a known adverse side-
effect of metformin therapy, which can be injurious in patients
with renal dysfunction. Preclinical and clinical evidences show that
the intestine appears to be an important source of metformin-
induced lactate production54,55 and it typically emerges during
meal absorption. This intestinal effect of metformin increases
anaerobic metabolism of glucose to lactate and its utilization in
the periphery. These observations are consistent with our basic
Intermittent treatment with metformin in old mice
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serum metabolic panel showing the signiﬁcant increase in
circulating lactate in non-fasting EOW mice. At the time of
sacriﬁce, the liver metabolome of EOW mice on metformin
revealed a signiﬁcant reduction in lactate, which may be the result
of its increased conversion to pyruvate and cycling back to
glucose via gluconeogenesis.46 Taken as a whole, these ﬁndings
offer a promising use of metformin in combatting ailments of
aging, although gastrointestinal intolerance, lactic acidosis, and
kidney failure have contributed to the adverse side-effects
associated with metformin use.56 Based on our results, it should
be emphasized the importance of optimizing the schedule of
metformin administration in order to gain the most health
beneﬁts.
Focusing on the molecular underpinnings of metformin action,
transcriptomic and metabolomics analyses have been performed
on liver tissue extracts from 2-year-old mice fed SD and mice on
intermittent metformin protocol for 17 weeks. Microarray analysis
illustrated the fact that EOW treatment impacted hepatic
expression of several metabolically-relevant genes, including
those encoding the transcriptional activator SREBF1—required
for lipid homeostasis, the transcriptional coactivator PGC-1α—
implicated in the regulation of genes involved in energy
metabolism, and SOCS2—a negative regulator in the GH/IGF-
1 signaling pathway. The increase in Angptl4 expression in EOW
livers is consistent with earlier reports showing the contribution of
this liver-expressed serum hormone in the regulation of glucose
homeostasis, lipid metabolism, and insulin sensitivity.57 Like
metformin, long-term CR and exercise increase plasma ANGPTL4
levels in humans58 whereas decreased expression of Angptl4 has
been associated with type 2 diabetes.57 Lipin-1 plays a central role
in mTORC1-dependent regulation of lipogenesis by SREBP159 and
we found that Lpin1 mRNA levels were signiﬁcantly upregulated
in EOW and 2WM livers together with an upregulation in pathways
related to ribosome/translation. To what extent does the
upregulation of genes encoding cholesterol and sterol biosyn-
thetic enzymes and that of key proteins implicated in translation
regulation antagonizes the pro-longevity effect of metformin
remains to be determined. Noteworthingly, increases in lipopro-
tein cholesterol concentrations are associated with coronary
atherosclerosis and shortened lifespan.60
Divergence between EOW and 2WM liver transcriptome was
observed, notably with regard to GO Terms associated with
mitochondrial inner membrane and mitochondrion, which could
indicate the importance of optimizing the intermittent metformin
treatment protocol for optimum beneﬁts. We performed an
exploratory data analysis aimed at visualizing the main character-
istics of the current gene expression signatures with that of our
recent CR study in male C57BL/6 J mice at 24 months of age.32 The
analysis suggests great similarity in the gene expression proﬁles
between CR and EOW, but not 2WM (Fig. 3j, k). Nevertheless, we
observed differential regulation of lipid and cholesterol metabo-
lism between metformin treatment and CR in these old mice.
Liver metabolomics analysis indicated the production of the
oncometabolite 2-hydroxyglutarate from the tricarboxylic acid
intermediate α-ketoglutarate. 2-Hydroxyglutarate is a known
activator of mTOR through inhibition by the ternary complex
between mTOR and the KDM4A-DEPTOR complex.61 KDM4A is an
α-ketoglutarate-dependent enzyme of the Jumonji family of lysine
demethylases that was recently found to act as a key regulator in
the metabolic switch between mitochondrial oxidation and
glycolysis,62 and to regulate senescence by targeting methylated
p53 for degradation.63 Increase in nutrient availability promotes
KDM4A-mediated ribosome biogenesis for the translation of RNA
into protein,64 a very costly energy-consuming process that
reduces life expectancy.65 It is possible that the inability of
metformin to extend mouse lifespan when treatment was started
late in life stemmed partly from the fact that 2-hydroxyglutarate
levels were elevated with an upregulation of genes associated
with ribosome biogenesis and assembly (Supplementary
Table S4c). In contrast, inhibition of mTOR activity with concurrent
activation of AMPK by rapamycin prolongs lifespan even when
given in old mice.66 Therefore, metformin and rapalogs may exert
cooperative effects at the level of the energy-sensing AMPK and
diminished expenditure of cellular energy required for protein
translation.
Tryptophan has been recently identiﬁed as a putative biomarker
for type 2 diabetes risk67 and reduction in its intake appear to
elicit beneﬁcial health and lifespan effects.68 In earlier studies,
tryptophan degradation into kynurenine intermediates and
production of 3-indoxyl sulfate and related indoles such as
indole-3-lactate have been found to elicit proinﬂammatory and
adverse events on the cardiovascular and renal systems.69,70 Our
metabolomics analysis revealed signiﬁcant elevation in 3-indoxyl
sulfate and/or indole-3-lactate in plasma of old EOW and 2WM
mice, indicative of renal toxicity (Fig. 2i) with associated
perturbation in glutathione biosynthesis and increased oxidative
stress.70 Indeed, under metabolic stress conditions and with aging,
the antioxidant defense system weakens and gives rise to a
system-wide increase in pro-oxidative biomarker levels. Tissues
such as the liver can dramatically increase the rate of hepatic
glutathione synthesis by activating the transsulfuration pathway,
which forms cystathionine from homocysteine, and release 2-
hydroxybutanoic acid upon cleavage of cystathionine to cysteine.
In time of need, glutamine is converted to glutamic acid, and
along with glycine and cysteine, these amino acids are
incorporated into glutathione. Herein, the marked increase in
insulin sensitivity (lower HOMA-IR index) and signiﬁcant elevation
in plasma 2-hydroxybutanoic acid in old EOW mice was consistent
with active transsulfuration pathway.
Hepatic conversion of glucose into fatty acids generates
palmitoleic acid, a metabolite implicated in the regulation and
pathophysiology of insulin action and glucose metabolism. A
study on the relationship between palmitoleic acid and metabolic
risk revealed that circulating palmitoleate is positively associated
with greater adiposity, higher triglycerides, and greater insulin
resistance in humans.71 Herein, EOW livers had signiﬁcant
reduction in palmitoleic acid, which is consistent with improved
insulin sensitivity and lower hepatic triglyceride content.
To conclude, the metabolic effects of metformin EOW when
initiated in late-life were associated with an overall improvement
Fig. 4 Identiﬁcation of hepatic and serum metabolites in SD-fed mice subjected to intermittent metformin treatment. a Volcano plots of 136
metabolites quantiﬁed in the liver and serum of 108-week-old mice maintained for 17 weeks on EOW or 2WM (Liver: SD, n= 10; EOW, n= 5;
2WM, n= 6; serum: SD, n= 10; EOW, n= 6; 2WM, n= 6). Signiﬁcantly altered metabolites are labeled in blue (fold change≥ 1.25 in both
directions, P≤ 0.05). b Venn diagrams of upregulated (red) and downregulated (blue) metabolites in the livers (left panel) and serum (right
panel) of mice following EOW–SD and 2WM–SD pairwise comparisons. c Graphical representation of the signiﬁcant metabolites shared by
EOW (plotted in blue) and 2WM (plotted in red) normalized to SD controls in the liver (upper) and serum (bottom). See Supplementary
Tables S6a and S6b for complete list of signiﬁcantly altered metabolites. Data are represented as the mean ± s.e.m. d Schematic diagram of
select metabolic pathways induced by EOW treatment based on the liver and serum metabolite proﬁles. Metabolism of organic sulfur
compounds is also depicted. Red and pink colors represent increased metabolites and blue and gray colors represent decreased metabolites
in serum and liver, respectively. H2S, production of hydrogen sulﬁde measured in Supplementary Fig. S1g. Data are represented as the mean
± s.e.m; n= 6 biological replicates per group, 23–24 months of age, 17–18 months on diet
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on health without an extension in lifespan as compared to control
mice. A combination of confounding factors such as adiposity,
energy overconsumption (ad libitum feeding) and related
weight gain, mitochondrial dysfunction, and incidence of cancer
could explain why metformin was unable to counterbalance these
adverse life-shortening events despite exhibiting favorable
markers of lower metabolic risk. Thus, additional longitudinal
studies will need to carefully assess the effects of intermittent
metformin treatment introduced at young to middle-age and
how gender and rodent genetic background may modify or
confound metformin’s effectiveness at improving healthspan, and
possibly lifespan. Targeting lifespan extension is a very complex
endeavor especially when a given intervention (e.g., metformin) is
provided in late-life once evolutionarily conserved molecular
pathways are already impaired, with genome stability loss, DNA
repair defects, and chronic oxidative stress to name of few. The
fact that metformin did not generate adverse outcomes in very
old mice is a reassuring safety data possibly for humans that start
metformin earlier in life and want to continue it into old age.
Further focus on classical hallmarks of aging should provide new
insights into whether/how improving healthspan can lead to
lifespan extension.
MATERIALS AND METHODS
Full details are provided in the Supplementary Information section.
Animals and diets
Animal procedures, housing and diets were in accordance with the
guidelines issued by the Intramural Research Program of the National
Institutes of Health protocol number 444TGB2016. Male C57BL/6 mice at
104 weeks of age were purchased from the National Institute on Aging
Aged Rodent Colony from Charles River. The C57BL/6 mice maintained on
a standard puriﬁed mouse diet (AIN-93G) for a month were randomly
distributed to avoid differences in starting body weight average between
the 3 experimental groups. Control group was kept on standard diet (SD; n
= 68) until their death while the other groups of mice were fed SD plus 1%
metformin following different on-and-off feeding protocols. Feedings
protocol consist of every other week (EOW; n = 64) and two consecutive
weeks each month (2WM; n = 67) with AIN-93G plus 1% metformin until
their death. Sample size estimate to ensure adequate power to detect
change in maximum lifespan was carried out based on our previous
published work. Pure metformin was obtained from Farmhispania (Farm-
hispania S.A., Barcelona, Spain) and mixed to homogeneity during
manufacturing of the diets (Dyets Inc., Bethlehem, PA). The chow was
produced every 3 months during the length of the study, never was
permitted to exceed 50 °C and was kept away from light whenever
possible to ensure the stability of metformin (the light/dark cycle in the
mouse facility was not altered). The mice were on a light:dark 12:12-h
schedule and maintained between 20–22 °C with 30–70% relative humidity
according to animal protocols and NIH guidelines. Food intake and body
weight were measured on a biweekly basis for the duration of the study for
control group and weekly for metformin fed mice. Body temperature was
biweekly measured through an implantable temperature transponder
system (IPTT-300, Bio Medic Data Systems). The transponders were
implanted under the skin on the back of the animals between the
shoulder blades using the provided instrument. The animals were allowed
to heal and recover for a minimum of one week after the implantation
before measurements were commenced. Survival curves were plotted
using the Kaplan–Meier method, which includes all available animals at
each time point. The criteria for euthanasia was based on an independent
assessment by a veterinarian, according to AAALAC guidelines and only
cases, where the condition of the animal was considered incompatible
with continued survival, are represented in the curves. Animals removed at
sacriﬁce for experimental procedures were considered as censored deaths.
The following tests in animals were performed by non-blinded
investigators unless otherwise stated.
Body composition
Measurements of lean, fat, and ﬂuid mass in live mice were acquired by
NMR using the Minispec LF90 (Bruker Optics, Billerica, MA, USA) after
16 weeks of treatment.
Metabolic assessment
After 16 weeks of metformin treatment, mouse metabolic rate was
assessed by indirect calorimetry in open-circuit Oxymax chambers with
CLAMS (Columbus Instruments) as previously described.2 Movement (both
horizontal and vertical) was also monitored with beams that software
transforms into counts of beam breaks by the mouse.
Physical performance tests
A detailed explanation of all physical performance tests performed is
described in the Supplementary Information.
Lactate and glucose measurements
Because diet was changed every week for EOW mice and every 2
consecutive weeks for 2WM mice, lactate and glucose levels were
measured in 6-h fasted animals (n = 8–10) on the Friday of week 13, 14,
15, and 16 of treatment. Glucose and lactate concentrations in blood were
measured by tail venipuncture with the Blood Glucose Monitoring System
Breeze 2 (Bayer, Mishawaka, IN) and Lactate plus Meter (Nova Biomedical
Corporation, Waltham, MA), respectively.
Sample collection
After 17 weeks of treatment, a subgroup of non-fasted SD mice (n = 10)
and mice on EOW and 2WM metformin (n = 6 each) were euthanized for
experimental procedures. Glucose and lactate were measured from a drop
of tail blood, with lactate measured from the ﬁrst drop. Mice were
anesthetized with ketamine–xylazine (50mg kg−1 ketamine and 5mg kg−1
xylazine; 10 µL 10 g−1 of body weight), and then blood and various tissues
were collected as summarized in Supplementary Information.
Blood and serum markers
An aliquot of whole blood was mixed with EDTA and used for the direct
determination of HbA1c with an enzymatic kit (Crystal Chem, Downers
Grove, IL). Coagulated whole blood was centrifuged at 12000×g for 10 min,
and serum was aliquoted and kept at −80 °C. Serum leptin and adiponectin
levels were measured using ELISA kits (EMD Millipore Corporation, Billerica,
MA), and insulin levels were determined according to the manufacturer’s
protocol (Crystal Chem).
Histology and electron microscopy
Full methodological details for liver and kidney histology, and the
determination of fenestrations in the liver sinusoidal endothelium by
SEM can be found in Supplementary Information. Scoring was performed
by investigators blinded to the treatment groups.
Microarray analysis
Raw data were subjected to Z-normalization, as described elsewhere.72,73
PCA was performed on the normalized Z-scores of all of the detectable
probes in the samples using DIANE 6.0 software, available from: (http://
www.grc.nia.nih.gov/branches/rrb/dna/ diane_software.pdf). Signiﬁcant
genes were selected by the z-test < 0.05, false discovery rate < 0.30, as
well as z-ratio > 1.5 in both directions and ANOVA p value < 0.05.
Methodological details can be found in the Supplementary Information.
Quantitative real-time PCR and Western blotting
Details can be found in the Supplementary Information.
Metabolomics
Metabolomics analysis on mouse liver extracts and serum was performed
by the UC Davis West Coast Metabolomics Center as previously
described.32 Methodological details can be found in the Supplementary
Information.
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Determination of hydrogen sulﬁde levels
The measure of hydrogen sulﬁde was carried out in liver extracts following
the methodological details previously described.26 Quantiﬁcation was
performed by volume densitometry using ImageJ software.
Determination of metformin levels
Method to measure metformin levels in mouse serum (n = 12) and liver
homogenates (n = 14) was performed using a LC-MS/MS method devel-
oped at SRI International (Menlo Park, CA), as described in Supplementary
Information. Lower limits of quantitation for the assay was 40 ngml−1 in
serum and 186 ng g−1 tissue in liver.
Statistics
Equal variance and normal distribution tests were performed to select an
appropriate statistical approach for each analysis. Unless otherwise stated,
a non-parametric Kruskal–Wallis test followed by Dunn’s multiple
comparisons test was used. For longevity studies, Gehan–Breslow-
Wilcoxon statistical test was used. Analyses were performed using
GraphPad Prism v. 6 (GraphPad Software, Inc., La Jolla, CA). In all
experiments, results are represented as the mean ± SEM, with p values <
0.05 considered signiﬁcant.
Data availability
Microarray data have been deposited in the Gene Expression Omnibus
database under accession code GSE97074. All relevant data that support
the ﬁndings of this study are included in this published article (and
its Supplementary information ﬁles), or are available from the correspond-
ing authors on reasonable request.
ACKNOWLEDGEMENTS
We thank Federico Butelman from Farmhispania S.A., a FDA-approved cGMP
company, for providing us with the metformin used in this mouse study; E. Lehrmann
and P. Bastian for microarray assistance; D. Boyer and D. Nines for animal care;
Vincent Guiterrez, Devin Wahl, Marta Garrido Novelle, and Nancy Zhang for mouse
physical performance tests. This research was supported, in part, by the Intramural
Research Program of the NIA, NIH.
AUTHOR CONTRIBUTIONS
I.A. conducted the longevity study and statistical analysis of survival data, performed
sac/necropsy of animals and gross histopathology, performed liver histology and
scoring, carried out NMR and metabolic studies and ELISAs, analyzed data, and
discussed data. S.J.M. carried out experiments (sac, liver histology and scoring, NMR
and metabolic studies), prepared liver samples for scanning electron microscopy,
analyzed data, and discussed data. V.H. performed kidney evaluation and scoring,
analyzed data, and discussed data. V.C.C., D.G.L., A.W. carried out scanning electron
microscopy and scoring, analyzed data, and discussed data. D.R.L., H.M., I.N.E., C.H., J.
R.M. conducted experiments and discussed the data. M.B. analyzed microarray and
metabolomics data, discussed data, created illustrations, and wrote the manuscript. R.
de C. planned and supervised the study, analyzed data and discussed the data,
reviewed and edited the manuscript. All authors gave ﬁnal approval of the
completed version of the manuscript.
ADDITIONAL INFORMATION
Supplementary information accompanies the paper on the npj Aging and
Mechanisms of Disease website (https://doi.org/10.1038/s41514-017-0018-7).
Competing interests: The authors declare thst they have no competing ﬁnancial
interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.
REFERENCES
1. US Food and Drug Administration. Metformin Information https://www.fda.gov/
Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/
ucm493293.htm (2017).
2. Martin-Montalvo, A. et al. Metformin improves healthspan and lifespan in mice.
Nat. Commun. 4, 2192 (2013).
3. Anisimov, V. N. et al. If started early in life, metformin treatment increases life
span and postpones tumors in female SHR mice. Aging (Albany NY) 3, 148–157
(2011).
4. Strong, R. et al. Longer lifespan in male mice treated with a weakly estrogenic
agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. Aging Cell
15, 872–884 (2016).
5. De Haes, W. et al. Metformin promotes lifespan through mitohormesis via the
peroxiredoxin PRDX-2. Proc. Natl. Acad. Sci. USA 111, 2501–2509 (2014).
6. Cabreiro, F. et al. Metformin retards aging in C. elegans by altering microbial
folate and methionine metabolism. Cell 153, 228–239 (2013).
7. Owen, M. R., Doran, E. & Halestrap, A. P. Evidence that metformin exerts its anti-
diabetic effects through inhibition of complex 1 of the mitochondrial respiratory
chain. Biochem. J. 348, 607–614 (2000).
8. El-Mir, M. Y. et al. Dimethylbiguanide inhibits cell respiration via an indirect effect
targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223–228 (2000).
9. Madiraju, A. K. et al. Metformin suppresses gluconeogenesis by inhibiting mito-
chondrial glycerophosphate dehydrogenase. Nature 510, 542–546 (2014).
10. Kalender, A. et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag
GTPase-dependent manner. Cell. Metab. 11, 390–401 (2010).
11. Takiyama, Y. et al. Tubular injury in a rat model of type 2 diabetes is prevented by
metformin: a possible role of HIF-1α expression and oxygen metabolism. Diabetes
60, 981–992 (2011).
12. Chen, S. C. et al. Metformin suppresses adipogenesis through both AMP-activated
protein kinase (AMPK)-dependent and AMPK-independent mechanisms. Mol. Cell
Endocrinol. 440, 57–68 (2017).
13. Foretz, M. et al. Metformin inhibits hepatic gluconeogenesis in mice indepen-
dently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin.
Invest. 120, 2355–2369 (2010).
14. Wu, L. et al. An ancient, uniﬁed mechanism for metformin growth inhibition in C.
elegans and cancer. Cell 167, 1705–1718 (2016).
15. Vazquez-Martin, A., Oliveras-Ferraros, C. & Menendez, J. A. The antidiabetic drug
metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of
the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8, 88–96
(2009).
16. Vazquez-Martin, A. et al. Metformin limits the tumourigenicity of iPS cells without
affecting their pluripotency. Sci. Rep. 2, 964 (2012).
17. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks
of aging. Cell 153, 1194–1217 (2013).
18. Menendez, J. A. et al. Metformin and the ATM DNA damage response (DDR):
accelerating the onset of stress-induced senescence to boost protection against
cancer. Aging (Albany NY) 3, 1063–1077 (2011).
19. Novelle, M. G., Ali, A., Diéguez, C., Bernier, M. & de Cabo, R. Metformin: a hopeful
promise in aging research. Cold Spring Harb. Perspect. Med. 6, a025932 (2016).
20. Smith, D. L. Jr. et al. Metformin supplementation and life span in Fischer-344 rats.
J. Gerontol. A. Biol. Sci. Med. Sci. 65, 468–474 (2010).
21. Onken, B. & Driscoll, M. Metformin induces a dietary restriction-like state and the
oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and
SKN-1. PLoS One 5, e8758 (2010).
22. Barzilai, N., Crandall, J. P., Kritchevsky, S. B. & Espeland, M. A. Metformin as a tool
to target aging. Cell Metab. 23, 1060–1065 (2016).
23. Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human
studies revisited. FASEB J. 22, 659–661 (2008).
24. DeFronzo, R., Fleming, G. A., Chen, K. & Bicsak, T. A. Metformin-associated lactic
acidosis: current perspectives on causes and risk. Metabolism 65, 20–29 (2016).
25. Perry, R. J., Samuel, V. T., Petersen, K. F. & Shulman, G. I. The role of hepatic lipids
in hepatic insulin resistance and type 2 diabetes. Nature 510, 84–91 (2014).
26. Hine, C. et al. Endogenous hydrogen sulﬁde production is essential for dietary
restriction beneﬁts. Cell 160, 132–144 (2015).
27. Kim, I. H., Kisseleva, T. & Brenner, D. A. Aging and liver disease. Curr. Opin.
Gastroenterol. 31, 184–191 (2015).
28. Mohamad, M. et al. Ultrastructure of the liver microcirculation inﬂuences hepatic
and systemic insulin activity and provides a mechanism for age-related insulin
resistance. Aging Cell 15, 706–715 (2016).
29. Finck, B. N. et al. Lipin 1 is an inducible ampliﬁer of the hepatic PGC-1α/PPARα
regulatory pathway. Cell Metab. 4, 199–210 (2006).
30. Guillén, N. et al. Microarray analysis of hepatic gene expression identiﬁes new
genes involved in steatotic liver. Physiol. Genomics 37, 187–198 (2009).
31. Zhou, Y., Jiang, L. & Rui, L. Identiﬁcation of MUP1 as a regulator for glucose and
lipid metabolism in mice. J. Biol. Chem. 284, 11152–11159 (2009).
32. Mitchell, S. J. et al. Effects of sex, strain, and energy intake on hallmarks of aging
in mice. Cell Metab. 23, 1093–1112 (2016).
Intermittent treatment with metformin in old mice
I Alfaras et al.
12
npj Aging and Mechanisms of Disease (2017)  16 Published in partnership with the Japanese Society of Anti-Aging Medicine
33. Knopf, J. L., Gallagher, J. F. & Held, W. A. Differential, multihormonal regulation of
the mouse major urinary protein gene family in the liver. Mol. Cell Biol. 3,
2232–2240 (1983).
34. Kang, H. S. et al. Metformin stimulates IGFBP-2 gene expression through PPAR-
alpha in diabetic states. Sci. Rep. 6, 23665 (2016).
35. Kang, H. S. et al. Regulation of IGFBP-2 expression during fasting. Biochem. J. 467,
453–460 (2015).
36. Leiser, S. F. et al. Cell nonautonomous activation of ﬂavin-containing mono-
oxygenase promotes longevity and health span. Science 350, 1375–1378 (2015).
37. Duca, F. A. et al. Metformin activates a duodenal Ampk-dependent pathway to
lower hepatic glucose production in rats. Nat. Med. 21, 506–511 (2015).
38. Wu, T. et al. Metformin reduces the rate of small intestinal glucose absorption in
type 2 diabetes. Diabetes Obes. Metab. 19, 290–293 (2017).
39. Liu, X., Romero, I. L., Litchﬁeld, L. M., Lengyel, E. & Locasale, J. W. Metformin
targets central carbon metabolism and reveals mitochondrial requirements in
human cancers. Cell. Metab. 24, 728–739 (2016).
40. Benjamin, D. et al. Syrosingopine sensitizes cancer cells to killing by metformin.
Sci. Adv. 2, e1601756 (2016).
41. Noren Hooten, N. et al. Metformin-mediated increase in DICER1 regulates
microRNA expression and cellular senescence. Aging Cell 15, 572–581 (2016).
42. Templeman, N. M. et al. Reduced circulating insulin enhances insulin sensitivity in
old mice and extends lifespan. Cell Rep. 20, 451–463 (2017).
43. Tang, X. et al. Metformin increases hepatic leptin receptor and decreases stea-
tosis in mice. J. Endocrinol. 230, 227–237 (2016).
44. Aubert, G., Mansuy, V., Voirol, M. J., Pellerin, L. & Pralong, F. P. The anorexigenic
effects of metformin involve increases in hypothalamic leptin receptor expres-
sion. Metabolism 60, 327–334 (2011).
45. Bridges, H. R., Jones, A. J., Pollack, M. N. & Hirst, J. Effects of metformin and other
biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 462,
475–487 (2014).
46. Schommers, P. et al. Metformin causes a futile intestinal-hepatic cycle which
increases energy expenditure and slows down development of a type 2 diabetes-
like state. Mol. Metab. 6, 737–747 (2017).
47. Mulligan, J. D., Gonzalez, A. A., Kumar, R., Davis, A. J. & Saupe, K. W. Aging elevates
basal adenosine monophosphate-activated protein kinase (AMPK) activity and
eliminates hypoxic activation of AMPK in mouse liver. J. Gerontol. A Biol. Sci. Med.
Sci. 60, 21–27 (2005).
48. Jamieson, H. A. et al. Caloric restriction reduces age-related pseudocapillarization
of the hepatic sinusoid. Exp. Gerontol. 42, 374–378 (2007).
49. Cogger, V. C. et al. Dietary macronutrients and the aging liver sinusoidal endo-
thelial cell. Am. J. Physiol. Heart Circ. Physiol. 310, H1064–H1070 (2016).
50. Fontana, L. et al. Aging promotes the development of diet-induced murine
steatohepatitis but not steatosis. Hepatology 57, 995–1004 (2013).
51. S. Jiang et al. (2017) AMPK orchestrates an elaborate cascade protecting tissue
from ﬁbrosis and aging. Ageing Res. Rev. 38, 18–27
52. Ogrodnik, M. et al. Cellular senescence drives age-dependent hepatic steatosis.
Nat. Commun. 8, 15691 (2017).
53. Neyrinck, A. M. et al. Spirulina protects against hepatic inﬂammation in aging: an
effect related to the modulation of the gut microbiota? Nutrients https://doi.org/
10.3390/nu9060633 (2017).
54. Pénicaud, L., Hitier, Y., Ferré, P. & Girard, J. Hypoglycaemic effect of metformin in
genetically obese (fa/fa) rats results from an increased utilization of blood glu-
cose by intestine. Biochem. J. 262, 881–885 (1989).
55. Bailey, C. J., Wilcock, C. & Scarpello, J. H. B. Metformin and the intestine. Diabe-
tologia 51, 1552–1553 (2008).
56. McCreight, L. J., Bailey, C. J. & Pearson, E. R. Metformin and the gastrointestinal
tract. Diabetologia 59, 426–435 (2016).
57. Xu, A. et al. Angiopoietin-like protein 4 decreases blood glucose and improves
glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc.
Natl. Acad. Sci. USA 102, 6086–6091 (2005).
58. Kersten, S. et al. Caloric restriction and exercise increase plasma ANGPTL4 levels
in humans via elevated free fatty acids. Arterioscler. Thromb. Vasc. Biol. 29,
969–974 (2009).
59. Peterson, T. R. et al. mTOR complex 1 regulates lipin 1 localization to control the
SREBP pathway. Cell 146, 408–420 (2011).
60. Verbeek, R., Hovingh, G. K. & Boekholdt, S. M. Non-high-density lipoprotein
cholesterol: current status as cardiovascular marker. Curr. Opin. Lipidol. 26,
502–510 (2015).
61. Carbonneau, M. et al. The oncometabolite 2-hydroxyglutarate activates the mTOR
signalling pathway. Nat. Commun. 7, 12700 (2016).
62. Wang, L. Y. et al. KDM4A Coactivates E2F1 to Regulate the PDK-Dependent
Metabolic Switch between Mitochondrial Oxidation and Glycolysis. Cell Rep. 16,
3016–3027 (2016).
63. Johmura, Y. et al. SCF(Fbxo22)-KDM4A targets methylated p53 for degradation
and regulates senescence. Nat. Commun. 7, 10574 (2016).
64. Salifou, K. et al. The histone demethylase JMJD2A/KDM4A links ribosomal RNA
transcription to nutrients and growth factors availability. Nat. Commun. 7, 10174
(2016).
65. Hofmann, J. W. et al. Reduced expression of MYC increases longevity and
enhances healthspan. Cell 160, 477–488 (2015).
66. Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically
heterogeneous mice. Nature 460, 392–395 (2009).
67. Chen, T. et al. Tryptophan predicts the risk for future type 2 diabetes. PLoS One
11, e0162192 (2016).
68. van der Goot, A. T. & Nollen, E. A. Tryptophan metabolism: entering the ﬁeld of
aging and age-related pathologies. Trends Mol. Med. 19, 336–344 (2013).
69. Barisione, C. et al. Indoxyl sulfate: a candidate target for the prevention and
treatment of cardiovascular disease in chronic kidney disease. Curr. Drug Targets
16, 366–372 (2015).
70. Yu, M., Kim, Y. J. & Kang, D. H. Indoxyl sulfate-induced endothelial dysfunction in
patients with chronic kidney disease via an induction of oxidative stress. Clin. J.
Am. Soc. Nephrol. 6, 30–39 (2011).
71. Mozaffarian, D. et al. Circulating palmitoleic acid and risk of metabolic abnorm-
alities and new-onset diabetes. Am. J. Clin. Nutr. 92, 1350–1358 (2010).
72. Cheadle, C., Vawter, M. P., Freed, W. J. & Becker, K. G. Analysis of microarray data
using Z score transformation. J. Mol. Diagn. 5, 73–81 (2003).
73. Lee, J. S. et al. Meta-analysis of gene expression in the mouse liver reveals
biomarkers associated with inﬂammation increased early during aging. Mech.
Ageing Dev. 133, 467–478 (2012).
74. Hilmer, S. N. et al. The effect of aging on the immunohistochemistry of apoli-
poprotein E in the liver. Exp. Gerontol. 39, 53–57 (2004).
75. Kim, S. Y. & Volsky, D. J. PAGE: parametric analysis of gene set enrichment. Bmc.
Bioinformatics 6, 144 (2005).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2017
Intermittent treatment with metformin in old mice
I Alfaras et al.
13
Published in partnership with the Japanese Society of Anti-Aging Medicine npj Aging and Mechanisms of Disease (2017)  16 
